Background: Continuous erythropoietin receptor activator (CERA; methoxy polyethylene glycol-epoetin beta) is a new erythropoiesis-stimulating agent with a prolonged half-life. The objective of this study was to select a starting dose of CERA for the treatment of anemia in non-small-cell lung cancer (NSCLC) patients.
3 weeks (Q3W) to patients with anemia and advanced NSCLC receiving chemotherapy. The CERA doses selected for this study, in particular 9 and 12 lg/kg s.c. Q3W, were extrapolated from the completed NSCLC study [50] and supported by the results of the other phase II study in NHL patients [51] .
patients and methods
Patients eligible for inclusion were adults (aged ‡ 18 years) with stage IIIB or IV NSCLC and a Hb level of £11 g/dl at screening. Patients were receiving first-line chemotherapy (without planned thoracic radiotherapy), which was planned to be continued for at least 9 weeks during the study. Additionally, patients had an Eastern Cooperative Oncology Group (ECOG) performance status grade of zero to two and a life expectancy of >6 months.
Key exclusion criteria included: a red blood cell (RBC) transfusion in the 4 weeks before the first planned dose of study medication, radiation therapy to >25% of bone marrow-containing areas in the 2 weeks before the first planned dose of study medication, any prior diagnosis of myeloid malignancy, known primary or metastatic malignancy of the central nervous system, functional iron deficiency (defined as both transferrin saturation <20% and serum ferritin <100 ng/ml), acute infection requiring parenteral antibiotic therapy, ESA therapy in the 4 weeks before study drug administration.
study design
This was a phase II, open-label, parallel, randomized (1 : 1 : 1 : 1), multicenter dose-finding study where patients received CERA or darbepoetin alfa s.c. injections over a 12-week treatment period [61] . The design and conduct of the study complied with the principles of good clinical practice, in accordance with the Declaration of Helsinki. The study was approved by local ethics committees and informed written consent was obtained from all patients before enrollment.
In order to ensure the safety of the patients, the trial included a strict safety monitoring plan, including an independent data safety monitoring board (DSMB). trial medication administration. Eligible patients were randomly allocated to one of the four treatment groups: CERA 6.3, 9, and 12 lg/kg Q3W or a reference group of patients treated with darbepoetin alfa administered s.c. at either 6.75 lg/kg Q3W or 2.25 lg/kg QW according to the approved local label. Randomization procedures ensured an 1 : 1 mix of the two darbepoetin alfa administration schedules. Patients received the first dose of study drug not >14 days after they were screened. The first dose of CERA or darbepoetin alfa was given on day 1 of the cycle, before the administration of chemotherapy.
dose modifications rules. Dose changes were made based upon the Hb levels in order to achieve and maintain the target Hb of 11-13 g/dl, but not to exceed 13 g/dl and to minimize rapid increases in Hb (i.e. >1.5 g/dl during a 3-week dosing period), e.g. each time Hb was >13.0 g/dl on the dosing day, CERA had to be stopped and resumed at 50% of the previous dose when Hb was £12 g/dl on the next scheduled administration or if Hb had increased by >1.5 g/dl at any time during a 3-week dosing period, the dose had to be reduced by 25% or 50% (investigator discretion) of the previous dose. If Hb had increased by <1 g/dl between two scheduled dose administrations of CERA and Hb had remained £11 g/dl, the dose had to be increased by 50% of the previous dose. Darbepoetin doses had to be modified according to local label [63] .
assessments. Hematology parameters, vital signs, and body weight were measured at screening and weekly thereafter. Blood samples for pharmacokinetic assessment and laboratory tests (blood chemistry and iron parameters) were taken on regularly scheduled weekly visits. Coagulation parameters were measured at baseline and repeated as soon as a patient experienced a thrombovascular event (TVE) while on study. Adverse events, iron supplementation, blood transfusions, and concomitant medications were documented throughout the course of the study.
end points
efficacy. The primary efficacy end point was the mean Hb change from baseline during weeks 5-13. Planned secondary end points included the following parameters: percentage of days within the target Hb therapeutic range (11-13 g/dl) per patient during the post-baseline period; percentage of patients with Hb rise from baseline ‡1 g/dl achieved by the first day of week 4 in the absence of RBC transfusion during the 4-week period; time to reaching the target Hb range (11-13 g/dl) during the post-baseline period; mean Hb values after reaching the Hb target 11-13 g/dl during the post-baseline period.
Since the aim of the study was also to develop dose modification rules for future phase III trials, end points to assess it were planned, e.g. percentage of patients with Hb < 13 g/dl after a dose modification; percentage of time with Hb < 13 g/dl after a dose modification; average Hb change between the last value before a dose increase, reduction or withholding; percentage of patients with at least one dose increase, dose reduction or withholding; total number of dose increases, dose reductions, or withholding.
safety. Safety end points included incidence of premature withdrawal, adverse events, clinical laboratory tests, vital signs, body weight, physical examination, and ECGs.
TVEs were considered safety parameters of special interest and were collected and monitored throughout the study. TVEs to be assessed belonged to the following categories: deep vein thrombosis, pulmonary embolism, arterial thrombosis, myocardial infarction, and cerebrovascular accident including transient ischemic attack.
statistical analyses
A total sample size of 200 (i.e. 50 patients per group) was selected on the basis of estimates of Hb variability and Hb increase during the treatment period (two-sided alpha test of 0.05) aiming to ensure 80% for differences of at least 0.5 g/dl between the treatment arms. However, this study was prematurely terminated when 153 patients had been randomized.
The efficacy of study medications was evaluated following the intentionto-treat (ITT) principle and included all patients who were randomized and received at least one dose of study medication. A per-protocol analysis was also carried out, which included patients who met the ITT criteria and had no major protocol violations that affected efficacy.
The primary efficacy variable was the mean Hb change from baseline during weeks 5-13. For analysis of the primary efficacy variable, patients who did not report any Hb measurements after week 5 were not included in the ITT analysis. The average value for a patient was calculated by taking the sum of the post-baseline Hb measurements (area under the curve) from week 5 through the last measurement on the basis of the trapezoidal method. The baseline value was the average of all Hb values collected from screening visit to baseline visit. Due to early termination of the trial, the planned secondary analyses were not carried out. to one of the three CERA dose groups and a darbepoetin alfa group.
The flow of patients in the core phase and in the 1-year follow-up is shown in Figure 1 .
A total of 19 (50%), 18 (50%), and 16 (42%) patients randomly assigned to receive CERA 6.3, 9, and 12 lg/kg, respectively, withdrew from the study before the termination of the trial. Fifteen patients (38%) in the darbepoetin alfa group withdrew prematurely. A total of five patients (one each in the CERA 6.3 and 9 lg/kg groups and three in the darbepoetin group) were prematurely withdrawn because of an adverse event. Death was reported as the reason for premature withdrawal for 8, 11, and 7 patients in the CERA 6.3, 9, and 12 lg/kg dose groups, respectively, and 3 patients in the darbepoetin alfa group. The median duration on study was similar across the six dose groups (80-85 days).
baseline characteristics
The demographics and clinical characteristics at baseline are provided in Table 1 . The majority of all patients in all dose groups had stage IV (63%-71%) NSCLC (Table 2) . A higher proportion (20%-21%) of patients in the darbepoetin alfa groups had large-cell lung carcinoma compared with other groups (range of 3%-11%). More patients in the CERA 6.3 and 9 lg/kg groups had lung adenocarcinoma histological type (47% and 45%, respectively) compared with the other groups (range of 30%-34%). The medical history of NSCLC has been summarized in Table 1 . Median Hb values at baseline were similar across all treatment groups (10.0-10.20 g/dl; Table 3 ). The majority of patients in this study had received previous anticancer therapy (76%, 86%, and 68% in the CERA 6.3, 9, and 12 lg/kg dose groups, respectively, and 72% in the darbepoetin dose group) that included antineoplastic treatment, surgery, or radiotherapy. The proportion of patients receiving either cisplatin or carboplatin was similar across all treatment groups (Table 2) .
efficacy
On the basis of following prespecified stopping rule in the DSMB charter: 'at least 3 times higher incidence of TVE or death in one of the CERA treatment arm compared to darbepoetin alfa group', the recommendation of the DSMB in agreement with the sponsor was to prematurely terminate the study. Therefore, for the assessment of efficacy, only the primary efficacy parameter of the mean Hb change from baseline during weeks 5-13 was analyzed. The primary efficacy parameter for the ITT population is provided in Table 3 .
tolerability and safety safety results. An imbalance in the number of deaths across treatment arms (8, 12 , and 9 in the CERA 6.3, 9, and 12 lg/kg groups, respectively, and 4 in the darbepoetin alfa group) was observed by the DSMB and the Sponsor leading to premature discontinuation of the trial. The causes of death in all four arms summarized in Table 4 were assessed as due to progressive lung cancer, comorbid illnesses, and cytotoxic effects of chemotherapy (febrile neutropenia or pancytopenia).
The majority of patients in all treatment groups experienced an adverse event (AE). As shown in Table 5 , despite the imbalance in deaths, the incidence of AEs (97%, 89%, and 100% in the 6.3, 9, and 12 lg/kg groups, respectively, and 97% in the darbepoetin group), severe AEs, and serious adverse events were comparable across all treatment groups and within the limits expected in a population of NSCLC patients receiving myelosuppressive chemotherapy. In addition, the incidence of TVEs was between 3% and 13% across the four treatment groups (Table 6 ) with a slightly greater incidence in the darbepoetin group.
The most frequently reported adverse events across the four treatment groups were nausea, anorexia, decreased Hb, neutropenia, vomiting, and fatigue. There were no clinically relevant changes in laboratory values and vital signs during the study in all dose groups or dose-dependent relationships for increasing blood pressure. In particular, no anti-CERA antibodies were detected.
one-year follow-up data
Additional analyses on mortality in the study were conducted which required the retrospective collection of information on survival status and disease progression from the randomized study population. The population for the follow-up study consisted of patients who either completed the initial study period (i.e. the treatment period and the 28-day post-treatment safety follow-up) or were prematurely withdrawn for a reason other than death.
Fifty-four patients in total consented to participate in the follow-up phase. In general, baseline characteristics were comparable between the two populations, the core study population and the patients who consented for the follow-up phase. The details of the patient disposition in the core phase and 1-year follow-up periods are given in Figure 1 .
Since the original protocol was not designed to prospectively evaluate the survival status of enrolled patients and it did not systematically collect information on their tumor assessment, an amendment became necessary, allowing the addition of a 1-year follow-up period after randomization in order to capture the survival and disease progression status of each patient. In the 1-year follow-up study, no patients received any study medication anymore. n represents the number of patients contributing to summary statistics. Percentages are on the basis of n (number of valid values). Percentages are not calculated if n < 10. Duration is presented in number of days from the randomization day. NSCLC, non-small-cell lung cancer; ITT, intention to treat; CERA, continuous erythropoietin receptor activator; Q3W, every 3 weeks; Q1W, weekly.
original article
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Some imbalances were observed among treatment groups (Table 7) : body mass index <18.5 at baseline was more frequent among CERA 12.5 lg/kg treatment group (31%); an ECOG of two at baseline was more frequent in the darbepoetin group (27%); lactate dehydrogenase (LDH) > upper limit and liver metastasis was most frequently observed in the 9 lg/kg CERA group (54% and 31%, respectively). The highest incidence of bone metastases was seen in the combined darbepoetin group (47%).
survival status 1 year after randomization. At 1 year postrandomization, there were 2 surviving patients (17%) in the 9 lg/kg treatment group. In the 6.3 lg/kg treatment group, 42% of patients (5 patients) were alive after 1 year; and the incidence was similar in the 12 lg/kg CERA [39% of patients (5 patients)] and in the darbepoetin alfa group [33% of patients (5 patients)]. Seven deaths occurred in both the 6.3 and 12 lg/kg treatment groups, there were nine deaths in the 9 lg/kg group and eight deaths in the combined darbepoetin groups. The 9 and 12 lg/kg groups each reported one patient as lost to follow-up; there were two such patients in the combined darbepoetin group.
An additional 31 of the 54 patients in the follow-up phase died during the 1-year follow-up. Most of these resulted from disease progression or cachexia; seven (54%), nine (69%), and seven (54%) in the 6.3, 9, and 12 lg/kg groups, respectively.
Kaplan-Meier curves of time to death for any reason. Overall survival for the original study population and the patients who participated in the 1-year follow-up was assessed using Kaplan-Meier (KM) estimates and is depicted in Figure 2 . The median time to death was shorter for the CERA 9 lg/kg group, [209 days hazard ratio (HR) 1.62], compared with the combined darbepoetin alfa group (263 days). Rates for median time to death in the CERA 6.3 lg and 12 lg/kg groups were comparable (323 days HR 1.04 and 340 days HR 0.68, respectively). However, caution should be used in the interpretation of these KM estimates; although this analysis allowed all patients participating in the study to be included, the limitation of this analysis in this study is that survival information for all patients was not available.
A retrospective adjudication of deaths, disease progressions and TVEs done by an adjudication committee independently from the assessments made by the study Steering Committee and the DSMB was inconclusive in terms of establishing an explanation of the observed imbalances in deaths and their potential relationship with study medication.
discussion
The primary objective of this phase II dose-finding study was to select the optimal start dose of CERA for future phase III trials and to confirm the tested dose modification rules. However, both objectives were not achieved in this study. No adequate dose-response relationship in terms of increase in mean and median Hb was observed across all three CERA dose groups. Although some Hb increase was observed, in none of the four study arms, the expected response to ESA treatment (an adequate response to ESA treatment is usually defined as an increase of at least 1 g/dl within 4 weeks) could be documented. Indeed, the lowest Hb change from baseline in weeks 5-13 was in the darbepoetin group (median of 20.14 g/dl). The failure to observe an increase in Hb over time even with darbepoetin which was administered according to the local label and prescribing practices was unanticipated and cannot be easily (47) 17 (45) 13 (34) 6 (30) 6 (32) Lung squamous cell 14 (37) 13 (34) 17 (45) 7 (35) 6 (32) Nondifferentiated NSCLC type 5 (13) 4 (11) 4 (11) 3 (15) 3 (16) ECOG performance status, n (%) 0 12 (32) 6 (16) 11 (29) 9 (45) 7 (37) 1 17 (45) 25 (66) 19 (50) 7 (35) 7 (37) 2 9 (24) 7 (18) 8 (21) 4 (20) (29) 11 (29) 12 (32) 6 (30) 5 (26) Cisplatin 19 (50) 20 (53) 18 (47) 11 (55) 11 (58) explained. In agreement with the DSMB recommendations which followed prespecified guidance criteria in the charter, this study was closed prematurely on the basis of the imbalance in deaths across treatment arms. In order to explore the unexplained and unexpectedly high death rate during the study, the original protocol was amended and an independent adjudication committee was appointed. Despite all these efforts, no clear association of the observed imbalances in death and study treatment or dose could be established nor was there an imbalance in the incidence of TVEs or an association of mortality and Hb response. However, the number of fatal events was smaller in the darbepoetin alfa arm.
One potential explanation for the increased overall death rate observed across all four study arms is that the population in this study had more significant comorbidities and more advanced NSCLC than projected, which could have resulted in an unusually high incidence of patients who do not respond to ESA therapies. There were some imbalances in some clinically relevant baseline characteristics with known effects on survival that favored the darbepoetin alfa group (Tables 2 and 7 ) such as shorter time to diagnosis, more ECOG zero, fewer liver metastases, and fewer respiratory disorders.
The possibility that ESAs might be associated with decreased survival in cancer patients has been raised on the basis of the results of several trials indicating poorer survival in the treatment arms receiving ESAs [52] [53] [54] .
As in the present study, concerns have also been raised about these studies regarding the advanced disease status of study participants, the use of higher Hb entry and target criteria, and imbalances in baseline characteristics and prognostic risk factors across the treatment arms that could potentially impact survival analyses.
A recent meta-analysis has shown that treatment with ESAs, in patients with cancer, increased mortality during the treatment period and worsened overall survival [60] . Hence, a 10% increase (P values NS) in the risk for overall mortality was estimated compared with the control arm in patients who underwent chemotherapy but this increased risk was less pronounced than in patients given other treatments such as radiotherapy or who were not receiving any treatment for their cancer (17% increase in mortality) [60] . This meta-analysis revealed a combined HR of 1.17, 95% confidence interval (CI) 1.06-1.30 for mortality and a HR of 1.6, 95% CI 1.0-1.12 for overall survival.
However, currently, the use of ESAs in the treatment of chemotherapy-induced anemia in lung cancer appears to be safe when administered according to guidelines [63, 64] , and a large randomized trial in advanced NSCLC patients receiving darbepoetin alfa (3000 patients planned) is recruiting patients (NCT00858364) [62] .
In order to fully understand the unexpected imbalance in death between the CERA and darbepoetin arms and to collect all available information which could potentially explain this finding, patients were enrolled into a 1-year long-term follow-up protocol which included a blinded adjudication of all relevant safety information available on these patients.
The proportion of patients [approximately one-third (17 of 54; see Figure 2 and Table 4 )] alive after 1 year appears Average of all Hb measurements before or on baseline day. The average Hb change from baseline was calculated using this baseline value. b 'Weeks 5-13' refer to from day 27 to the last Hb measurement in the study.
Hb, hemoglobin; ITT, intention to treat; CERA, continuous erythropoietin receptor activator; SE, standard error; SD, standard deviation.
original article Annals of Oncology consistent with the 1-year survival rate usually observed in NSCLC patients [55] . However, despite best efforts undertaken, it remains difficult to draw conclusions given the small number of patients in the 1-year follow-up study. Consistent with the core study period, the highest number of deaths was observed in the CERA 9 lg/kg group and the median time to death for patients who participated in the 1-year follow-up was overall shorter than in patients receiving darbepoetin. Furthermore, increased levels of LDH at baseline are also a known risk factor for survival because it is an indicator of disease activity [56] [57] [58] [59] . Almost all deaths occurring during the 1-year follow-up period were due to disease progression (86%-100% across all treatment groups); the exceptions were one case of tumor cachexia 
Consenting patients from institutional review board-approved study sites, 365 days after randomization. b Patient 5601, though incorrectly included in the follow-up population, died during the core phase of the study. c Patient 5602, though incorrectly included in the follow-up population, died during the core phase of the study. Table 5 . Summary of patients with adverse events (ITT) and one case of pneumonia, both in the CERA 6.3 lg/kg treatment group. Between 46% and 62% of the patients followed reported progressive disease during the 1-year extension period (28 of 54 patients), irrespective of survival status ( Table 4) . As in the core period, the smaller than expected number of participating patients makes it precarious to draw firm conclusions from the data collected during the core period and the 1-year study extension.
conclusions
In the present dose-finding study, none of the three CERA doses tested were associated with a significant Hb increase and no dose-response relationship was observed. The study was prematurely terminated due to an unexplained imbalance in the number of deaths which favored patients receiving darbepoetin. Most likely the observed differences were due to the severity of the underlying disease, differences in prognostic 
